Alphatec Holdings, Inc. (ATEC) stock

ATECNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 7/30

$7.07+0.01 (+0.14%)

Close on Nov 13, 2026Market cap $1.10BP/E –Yield –

Earnings

Alphatec's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Feb 23, 2027

Q4 FY2026 · estimated, after the close

Revenue, Q3 FY2026

$221.00M

+12.2% on a year earlier

Non-GAAP net income (loss) per share, Q3 FY2026

$0.09

$0.03 a year earlier

Latest guidance

Raised

Oct 29, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Alphatec's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q4 FY2026ended Dec 31, 2026	Feb 23, 2027Expected	–	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Oct 29, 2026after the close	$221.00M	+12.2%	-$0.03	$0.09	Release
Q2 FY2026ended Jun 30, 2026	Aug 4, 2026after the close	$214.00M	+15.1%	-$0.16	$0.07	Release
Q1 FY2026ended Mar 31, 2026	May 5, 2026after the close	–	–	–	–	Release
Q4 FY2025ended Dec 31, 2025	Feb 24, 2026after the close	$213.00M	+20.3%	-$0.14	$0.06	Release
Q3 FY2025ended Sep 30, 2025	Oct 30, 2025after the close	$197.00M	–	-$0.19	$0.03	Release
Q2 FY2025ended Jun 30, 2025	Jul 31, 2025after the close	$186.00M	+27.4%	-$0.27	$0.02	Release
Q1 FY2025ended Mar 31, 2025	May 1, 2025after the close	$169.00M	+22.5%	-$0.35	–	Release
Q4 FY2024ended Dec 31, 2024	Feb 26, 2025after the close	$177.00M	+28.3%	-$0.23	–	Release
Q3 FY2024ended Sep 30, 2024	Oct 30, 2024after the close	–	–	–	–	Release
Q2 FY2024ended Jun 30, 2024	Jul 31, 2024after the close	$146.00M	+24.8%	-$0.29	–	Release
Q1 FY2024ended Mar 31, 2024	May 7, 2024after the close	$138.00M	+26.6%	-$0.34	–	Release
Q4 FY2023ended Dec 31, 2023	Feb 27, 2024after the close	$138.00M	+30.2%	-$0.37	–	Release
Q3 FY2023ended Sep 30, 2023	Nov 6, 2023after the close	$118.00M	+31.1%	-$0.35	–	Release
Q2 FY2023ended Jun 30, 2023	Aug 3, 2023after the close	$117.00M	+39.3%	-$0.43	–	Release
Q1 FY2023ended Mar 31, 2023	May 4, 2023after the close	$109.00M	+53.5%	-$0.40	–	Release
Q4 FY2022ended Dec 31, 2022	Feb 28, 2023after the close	$106.00M	+43.2%	-$0.33	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 3, 2022after the close	$90.00M	+43.1%	-$0.35	–	Release
Q2 FY2022ended Jun 30, 2022	Aug 4, 2022after the close	$84.00M	–	-$0.36	–	Release
Q1 FY2022ended Mar 31, 2022	May 5, 2022after the close	$71.00M	–	-$0.43	–	Release
Q4 FY2021ended Dec 31, 2021	Mar 1, 2022after the close	$74.00M	–	-$0.40	–	Release
Q3 FY2021ended Sep 30, 2021	Nov 4, 2021after the close	$62.90M	–	-$0.43	–	Release
Q2 FY2021ended Jun 30, 2021	Jul 12, 2021before the open	–	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	Apr 8, 2021before the open	–	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Mar 5, 2021after the close	–	–	–	–	Filing
Q3 FY2020ended Sep 30, 2020	Oct 13, 2020after the close	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Alphatec's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
surgical revenue	FY2026	$805.00M	$890.00M	Lowered	Aug 4, 2026
total revenue	FY2026	$862.00M	$890.00M	Lowered	Oct 29, 2026
total revenue growth	FY2026	+15%	+17%	Lowered	Aug 4, 2026
adjusted EBITDAnon-GAAP	FY2026	$137.00M	$134.00M	Raised	Oct 29, 2026
adjusted EBITDAnon-GAAP	FY2026	$140.00M	$130.00M	Raised	Aug 4, 2026
free cash flownon-GAAP	FY2026	$10.00M	$20.00M	Lowered	Oct 29, 2026
free cash flownon-GAAP	FY2026	$20.00M	$20.00M	Reaffirmed	Aug 4, 2026

Guidance vs results

The last range Alphatec gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	Revenue	$760.00M	$765.00MΣ4Q	Above range

Guidance history

Every forecast Alphatec put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Oct 29, 2026	adjusted EBITDA	FY2026	$137.00M	Raised
Oct 29, 2026	free cash flow	FY2026	$10.00M	Lowered
Oct 29, 2026	total revenue	FY2026	$862.00M	Lowered
Aug 4, 2026	adjusted EBITDA	FY2026	$140.00M	Raised
Aug 4, 2026	free cash flow	FY2026	$20.00M	Reaffirmed
Aug 4, 2026	total revenue growth	FY2026	+15%	Lowered
Aug 4, 2026	surgical revenue	FY2026	$805.00M	Lowered
Aug 4, 2026	total revenue	FY2026	$882.00M	Raised
Aug 4, 2026	surgical revenue growth	FY2026	+17%	Raised
Aug 4, 2026	EOS revenue	FY2026	$77.00M	Lowered
Feb 24, 2026	adjusted EBITDA	FY2026	$134.00M	New
Feb 24, 2026	free cash flow	FY2026	$20.00M	New
Feb 24, 2026	total revenue	FY2026	$890.00M	New
Jan 12, 2026	adjusted EBITDA	FY2026	$130.00M	New
Jan 12, 2026	free cash flow	FY2026	$20.00M	New
Jan 12, 2026	total revenue	FY2026	$890.00M	New
Jan 12, 2026	EOS revenue	FY2026	$85.00M	Lowered
Jan 12, 2026	surgical revenue	FY2026	$805.00M	Lowered
Jan 12, 2026	total revenue growth	FY2026	+17%	New
Oct 30, 2025	non-GAAP adjusted EBITDA	FY2025	$91.00M	New
Oct 30, 2025	total revenue growth	FY2025	+24%	New
Oct 30, 2025	total revenue	FY2025	$760.00M	New
Oct 30, 2025	surgical revenue	FY2025	$684.00M	Lowered
Oct 30, 2025	EOS revenue	FY2025	$76.00M	Lowered
Jul 31, 2025	non-GAAP adjusted EBITDA	FY2025	$83.00M	Raised
Jul 31, 2025	total revenue	FY2025	$742.00M	Raised
May 1, 2025	non-GAAP adjusted EBITDA	FY2025	$78.00M	Raised
May 1, 2025	total revenue	FY2025	$734.00M	Raised
May 1, 2025	surgical revenue	FY2025	$658.00M	Lowered
May 1, 2025	EOS revenue	FY2025	$76.00M	Lowered
Feb 26, 2025	adjusted EBITDA	FY2025	$75.00M	Reaffirmed
Feb 26, 2025	total revenue	FY2025	$732.00M	Raised
Jan 13, 2025	adjusted EBITDA	FY2025	$75.00M	New
Jan 13, 2025	total revenue growth	FY2025	+20%	New
Jan 13, 2025	total revenue	FY2025	$732.00M	New
Jan 13, 2025	surgical revenue	FY2025	$657.00M	Lowered
Jan 13, 2025	EOS revenue	FY2025	$75.00M	Lowered
Oct 30, 2024	non-GAAP adjusted EBITDA	FY2024	$27.00M	Raised
Oct 30, 2024	total revenue to grow	FY2024	+25%	New
Oct 30, 2024	total revenue	FY2024	$605.00M	Raised
Oct 30, 2024	surgical revenue	FY2024	$540.00M	Lowered
Oct 30, 2024	EOS revenue	FY2024	$65.00M	Lowered
Jul 31, 2024	non-GAAP adjusted EBITDA	FY2024	$25.50M	Raised
Jul 31, 2024	total revenue	FY2024	$602.00M	Raised
May 7, 2024	non-GAAP adjusted EBITDA	FY2024	$23.00M	Raised
May 7, 2024	total revenue	FY2024	$601.00M	Raised
Feb 27, 2024	non-GAAP adjusted EBITDA	FY2024	$22.00M	New
Feb 27, 2024	total revenue	FY2024	$595.00M	New
Nov 6, 2023	non-GAAP adjusted EBITDA	FY2023	$3.00M	Raised
Nov 6, 2023	total revenue	FY2023	$472.00M	Raised
Aug 3, 2023	non-GAAP adjusted EBITDA	FY2023	$2.00M	New
Aug 3, 2023	total revenue	FY2023	$462.00M	Raised
May 4, 2023	total revenue	FY2023	$450.00M	Raised
Feb 28, 2023	total revenue	FY2023	$438.00M	Reaffirmed
Jan 9, 2023	total revenue	FY2023	$438.00M	New
Nov 3, 2022	total revenue	FY2022	$340.00M	Raised
Aug 4, 2022	total revenue	FY2022	$325.00M	Raised
May 5, 2022	total revenue	FY2022	$316.00M	Raised
Mar 1, 2022	total revenue	FY2022	$305.00M	New
Nov 4, 2021	total revenue	FY2021	$235.00M	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.